Precision intervention of cell type-specific targeting is required for future cancer immunotherapy.

Abstract

Immune checkpoint blockade has represented a break-through for the treatment of human cancers, but only a minority of patients obtain clinical bene fi ts from this therapy. A critical issue is how to shape the “ cold ” tumor, characterized by desert or suppressive immunity, into a “ hot ” phenotype [1